# US 2004/0019920 A1 · Transgenic animals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0019920 A1
- Document ID: US20040019920A1
- Status: Published application
- Kind: A1
- Application number: 10/385,763
- Filed: 2003-03-11
- Published: 2004-01-29
- Earliest claimed: 1998-11-19
- Assignees: Gala Design, Inc.
- Inventors: Robert D. Bremel; Gregory T. Bleck
- Web page: https://patentgrep.com/patent/US20040019920A1

## CPC

- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- C07K 14/005: from viruses
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2207/15: Humanized animals
- A01K 2217/00: Genetically modified animals
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/101: Bovine
- A01K 2267/01: Animal expressing industrially exogenous proteins
- C12N 2730/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.

## Claims

### Claim 1

A composition comprising a stably maintained recombinant mammalian zygote, wherein said zygote comprises a polynucleotide containing the proviral form of a retroviral vector integrated into the genome of said zygote.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said mammalian zygote is a bovine zygote.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said proviral form of said retroviral vector encodes a protein of interest.

### Claim 4 (depends on 1)

The method of claim 1, wherein said recombinant retroviral vector comprises Moloney murine leukemia virus long terminal repeat.

### Claim 5

A method for introducing a polynucleotide contained within the genome of a recombinant retrovirus into the genome of a mammalian zygote, comprising:
a) providing:
i) a mammalian zygote having a plasma membrane and a zona pellucida, said plasma membrane and said zona pellucida defining a perivitelline space;
ii) an aqueous solution comprising a polynucleotide contained within the genome of a recombinant retrovirus; and
b) introducing said solution comprising said polynucleotide contained within the genome of a recombinant retrovirus into said perivitelline space under conditions which permit the introduction of said polynucleotide contained within the genome of a recombinant retrovirus into the genome of said zygote, such that said polynucleotide is stably maintained.

### Claim 6 (depends on 5)

The method of claim 5, wherein the efficiency of said introduction of said polynucleotide contained within the genome of a recombinant retrovirus into the genome of said zygote, such that said polynucleotide is stably maintained is at least twenty percent.

### Claim 7 (depends on 5)

The method of claim 5, wherein said polynucleotide contained within the genome of a recombinant retrovirus encodes a protein of interest.

### Claim 8 (depends on 7)

The method of claim 7, further comprising the step of transferring said zygote into a mammalian female recipient that is hormonally synchronized to simulate early pregnancy, thereby giving a transferred embryo.

### Claim 9 (depends on 8)

The method of claim 8, further comprising the step of allowing said transferred embryo to develop to term.

### Claim 10 (depends on 7)

The method of claim 7, further comprising the step of identifying at least one transgenic offspring.

### Claim 11 (depends on 10)

A transgenic animal produced according to the method of claim 10.

### Claim 12 (depends on 10)

The method of claim 10, wherein said recombinant retrovirus comprises Moloney murine leukemia virus long terminal repeat.

### Claim 13 (depends on 12)

The method of claim 12, wherein said protein of interest is expressed by said transgenic offspring.

### Claim 14 (depends on 13)

The method of claim 13, wherein said protein of interest is expressed in at least one body fluid of said transgenic offspring.

### Claim 15 (depends on 13)

The method of claim 13, wherein said expression of said protein of interest is preferentially mammary-specific expression.

### Claim 16 (depends on 5)

The method of claim 5, wherein said recombinant retrovirus comprises a heterologous membrane-associated protein.

### Claim 17 (depends on 16)

The method of claim 16, wherein said heterologous membrane-associated protein is a G glycoprotein selected from a virus within the family Rhabdoviridae.

### Claim 18 (depends on 17)

The method of claim 17, wherein said G glycoprotein is selected from the group comprising the G glycoprotein of vesicular stomatitis virus, Piry virus, Chandipura virus, Spring viremia of carp virus, Rabies virus, and Mokola virus.

### Claim 19

A method for producing a transgenic non-human animal, wherein the genome of said transgenic non-human animal comprises a polynucleotide encoding a recombinant retrovirus and at least one protein of interest, comprising the steps of:
a) providing:
i) a non-human mammalian zygote having a plasma membrane and a zona pellucida, said plasma membrane and said zona pellucida defining a perivitelline space;
ii) an aqueous solution comprising a polynucleotide contained within the genome of a recombinant retrovirus;
b) introducing said solution comprising said polynucleotide contained within the genome of a recombinant retrovirus into said perivitelline space under conditions which permit the introduction of said polynucleotide contained within the genome of a recombinant retrovirus into the genome of said zygote, such that said polynucleotide is stably maintained in a recombinant zygote;
c) transferring said recombinant zygote into a non-human female mammalian recipient that is hormonally synchronized to simulate early pregnancy, thereby giving a transferred embryo;
d) allowing said transferred embryo to develop to term to produce a transgenic animal.

### Claim 20 (depends on 19)

The method of claim 19, wherein the said at least one protein of interest is expressed by said transgenic animal.

### Claim 21 (depends on 19)

The method of claim 19, wherein said recombinant retrovirus comprises Moloney murine leukemia virus long terminal repeat.

### Claim 22 (depends on 21)

The method of claim 21, wherein the efficiency of said introduction of said polynucleotide contained within the genome of a recombinant retrovirus into the genome of said zygote, such that said polynucleotide is stably maintained is at least twenty percent.

### Claim 23 (depends on 21)

The method of claim 21, wherein the expression of said polynucleotide is preferentially mammary-specific expressed.

### Claim 24 (depends on 20)

The method of claim 20, comprising the further step of mating said transgenic animal to a non-transgenic animal under conditions such that transgenic offspring are produced.

### Claim 25 (depends on 24)

The method of claim 24, wherein said transgenic offspring express said polynucleotide.

### Claim 26 (depends on 25)

The method of claim 25, wherein said expression of said polynucleotide is mammary-specific expression.

### Claim 27

A method for expressing a protein of wherein said protein of interest is encoded by a polynucleotide contained within the genome of a recombinant retrovirus, comprising the steps of:
a) providing:
i) a non-human mammalian zygote having a plasma membrane and a zona pellucida, said plasma membrane and said zona pellucida defining a perivitelline space;
ii) an aqueous solution comprising a polynucleotide encoding a protein of interest contained within the genome of a recombinant retrovirus; and
b) introducing said solution comprising said polynucleotide encoding a protein of interest contained within the genome of a recombinant retrovirus into said perivitelline space under conditions which permit the introduction of said polynucleotide contained within the genome of a recombinant retrovirus into the genome of said zygote, such that said polynucleotide is stably maintained;
c) allowing said zygote to develop into viable non-human animal, under conditions such that said protein of interest is expressed by said non-human animal.

### Claim 28 (depends on 27)

The method of claim 27, wherein said recombinant retrovirus comprises Moloney murine leukemia virus long terminal repeat.

### Claim 29 (depends on 27)

The method of claim 27, wherein said introduction of said polynucleotide contained within the genome of a recombinant retrovirus into the genome of said zygote, such that said polynucleotide is stably maintained is at least twenty percent.

### Claim 30 (depends on 27)

The method of claim 27, wherein said polynucleotide contained within the genome of a recombinant retrovirus encodes a viral protein.

### Claim 31 (depends on 30)

The method of claim 30, wherein said viral protein is hepatitis B surface antigen.

### Claim 32 (depends on 27)

The protein of interest expressed according to the method of claim 27.

### Claim 33 (depends on 27)

The method of claim 27, further comprising the step of d) harvesting said expressed protein of interest.

### Claim 34 (depends on 27)

The method of claim 27, wherein said expressed protein is expressed in the body fluids of said non-human animal.

### Claim 35 (depends on 34)

The method of claim 34, wherein said body fluids are selected from the group consisting of blood, milk, semen, and urine.

### Claim 36

A method for expressing a protein of interest wherein said protein of interest is encoded by a polynucleotide contained within the genome of a recombinant retrovirus, and said polynucleotide is integrated into the genome of a mammalian unfertilized oocyte, comprising the steps of:
a) providing:
i) an unfertilized mammalian egg comprising an oocyte having a plasma membrane and a zona pellucida, said plasma membrane and said zona pellucida defining a perivitelline space;
ii) an aqueous solution containing recombinant retrovirus, wherein said recombinant retrovirus comprises a polynucleotide encoding a protein of interest;
b) introducing said solution containing recombinant retrovirus into said perivitelline space under conditions which permit the infection of said oocyte to provide an infected oocyte;
c) contacting said infected oocyte with sperm under conditions which permit the fertilization of said infected oocyte to produce an embryo;
d) transferring said embryo into a hormonally synchronized mammalian recipient animal;
e) allowing said embryo to develop into at least one viable transgenic mammalian animal, under conditions such that said protein of interest is expressed by said transgenic mammalian animal.

### Claim 37 (depends on 36)

The method of claim 36, wherein said unfertilized oocyte is a pre-maturation oocyte.

### Claim 38 (depends on 37)

The method of claim 37, further comprising following the introduction of said solution containing infectious retrovirus into said pre-maturation oocyte, the further step of culturing said infected pre-maturation oocyte under conditions which permit the maturation of said pre-maturation oocyte.

### Claim 39 (depends on 36)

The method of claim 36, wherein said unfertilized oocyte is a pre-fertilization oocyte.

### Claim 40 (depends on 36)

The method of claim 36, further comprising identifying at least one transgenic offspring.

### Claim 41 (depends on 36)

The method of claim 36, wherein said mammal is a bovine.

### Claim 42 (depends on 36)

The method of claim 36, wherein said recombinant retrovirus comprises Moloney murine leukemia virus long terminal repeat.

### Claim 43 (depends on 42)

The method of claim 42, wherein said expression of said protein of interest is preferentially mammary specific expression.

### Claim 44 (depends on 43)

The method of claim 43, wherein said introduction of said polynucleotide contained within the genome of a recombinant retrovirus into the genome of said infected oocyte, such that said polynucleotide is stably maintained is greater than twenty percent.

### Claim 45 (depends on 36)

The method of claim 36, wherein said polynucleotide contained within the genome of a recombinant retrovirus encodes a viral protein.

### Claim 46 (depends on 45)

The method of claim 45, wherein said viral protein is hepatitis B surface antigen.

### Claim 47 (depends on 36)

The protein of interest expressed according to the method of claim 36.

### Claim 48 (depends on 36)

The method of claim 36, further comprising the step of f) harvesting said expressed protein of interest.

### Claim 49 (depends on 36)

The method of claim 36, wherein said expressed protein is expressed in the body fluids of said mammalian animal.

### Claim 50 (depends on 49)

The method of claim 49, wherein said body fluids are selected from the group consisting of blood, milk, semen, and urine.

### Claim 51 (depends on 36)

The method of claim 36, wherein said recombinant retrovirus comprises a heterologous membrane-associated protein.

### Claim 52 (depends on 51)

The method of claim 51, wherein said heterologous membrane-associated protein is a G glycoprotein selected from a virus within the family Rhabdoviridae.

### Claim 53 (depends on 52)

The method of claim 52, wherein said G glycoprotein is selected from the group comprising the G glycoprotein of vesicular stomatitis virus, Piry virus, Chandipura virus, Spring viremia of carp virus and Mokola virus.
